Skip navigation

Epilobium parviflorum Schreb. - in vitro study of biological action

Epilobium parviflorum Schreb. - in vitro study of biological action

Hevesi Tóth, Barbara, Houghton, P.J., Habtemariam, S., Milligan, S., Kalita, C.J., Purohit, A. and Kéry, Á. (2007) Epilobium parviflorum Schreb. - in vitro study of biological action. Planta Medica, 73 (9). P454. ISSN 0032-0943 (doi:

Full text not available from this repository.


Epilobium parviflorum Schreb. (Onagraceae) is used for the treatment of benign prostatic hyperplasia (BPH), which is regarded as an endocrine disorder caused by age-related hormone imbalance and increased oxidative damage [1,2,3]. Epilobium can moderate the obstructive and the irritative symptoms of BPH [1] but its biological action is not entirely identified. E. parviflorum is rich in phytosterols, flavonoids (myricetin, quercetin, kaempferol and their glycosides), phenolic acids, catechins, ellagi- and gallotannins [4]. The potential biological effects of Epilobium parviflorum Schreb. have been investigated, in respect to its antioxidant, anti-inflammatory, enzyme-inhibitory and anti-androgenic effect. The whole-plant water extract showed higher antioxidant effect (IC50=1.65±0.05µg/mL) in DPPH assay than Trolox or ascorbic acid and inhibited the lipid peroxidation examined in TBA assay (IC50=2.31±0.18mg/mL). In concentrations 0.20-15.00µg/mL the extract possessed a protective effect comparable to catalase enzyme (2500 IU/mL), against oxidative damage generated on fibroblast cells. The examination of the COX-inhibitory effect showed that E. parviflorum had an anti-inflammatory effect (IC50=1.38±0.08µg/mL). Investigation of steroid receptor binding ability and the aromatase enzyme-inhibition showed negative results in the concentration range examined.

Item Type: Article
Additional Information: Abstract for poster presented at 55th Annual Congress of the Society-for-Medicinal-Plant-ResearchSEP 02-06, 2007 Karl Franzens Univ, Graz, Austria
Uncontrolled Keywords: Epilobium parviflorum Schreb, benign prostatic hyperplasia, BPH
Subjects: R Medicine > RM Therapeutics. Pharmacology
Faculty / School / Research Centre / Research Group: Faculty of Engineering & Science > School of Science (SCI)
Related URLs:
Last Modified: 13 Feb 2020 10:01

Actions (login required)

View Item View Item